Fig. 2
Distribution of patients’ diabetes characteristics according to the 6 profiles created in latent profile analysis. Boxplot of patients’ (a) insulin sensitivity (HOMA2%-S) calculated by Homeostasis Model Assessment (HOMA2), (b) beta-cell function (HOMA2%-β) calculated by Homeostasis Model Assessment (HOMA2), (c) hyperbolic product of insulin sensitivity and beta-cell function (HOMA2%-βxS), (d) Age at diagnosis of type 2 diabetes mellitus, (e) HbA1c collected at the time of HOMA2 assessment, (f) Glucose-lowering therapy (GLT) total dose, used just before the HOMA2 assessment, and expressed in Defined Daily Dose (one unrepresented outlier patient in profile 6 whose GLT total DDD = 6.88), (g) BMI (kg/m2; one unrepresented outlier patient in profile 3 whose BMI = 58.56 kg/m2), and (h) duration of diabetes until the last endocrinology consultation, according to the 6 profiles created by the Latent Profile Analysis (LPA). Statistical comparisons between profiles were performed using a Kruskal-Wallis test